The estimated Net Worth of Susannah Gray is at least $501 mil dollars as of 24 November 2020. Susannah Gray owns over 20,000 units of 4D Molecular Therapeutics stock worth over $500,713 and over the last 4 years Susannah sold FDMT stock worth over $0.
Susannah has made over 1 trades of the 4D Molecular Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Susannah bought 20,000 units of FDMT stock worth $540,000 on 24 November 2020.
The largest trade Susannah's ever made was buying 20,000 units of 4D Molecular Therapeutics stock on 24 November 2020 worth over $540,000. On average, Susannah trades about 1,176 units every 0 days since 2020. As of 24 November 2020 Susannah still owns at least 31,852 units of 4D Molecular Therapeutics stock.
You can see the complete history of Susannah Gray stock trades at the bottom of the page.
Susannah's mailing address filed with the SEC is C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM, MA, 02451.
Over the last 4 years, insiders at 4D Molecular Therapeutics have traded over $22,158,915 worth of 4D Molecular Therapeutics stock and bought 2,479,347 units worth $51,074,981 . The most active insiders traders include Global Investors Lp Viking ..., John F Milligan, eGlobal Investors Lp Viking .... On average, 4D Molecular Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of $1,516,666. The most recent stock trade was executed by Scott Bizily on 19 August 2024, trading 500 units of FDMT stock currently worth $3,245.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
4D Molecular Therapeutics executives and other stock owners filed with the SEC include: